Align Technology (Nasdaq: ALGN) sets $200M open‑market buyback
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Align Technology, Inc. plans to repurchase $200.0 million of its common stock through open market transactions under its previously approved $1.0 billion stock repurchase program. The purchases will be made under a Rule 10b5-1 trading plan and funded with existing cash.
The repurchases are expected to be completed by October 2026. As of March 31, 2026, Align had approximately 71.6 million shares outstanding and $1,059.8 million in cash and cash equivalents, including $206.6 million held domestically to support the latest trading plan.
Positive
- None.
Negative
- None.
Insights
Align earmarks $200M for open‑market buybacks funded from cash.
Align Technology is directing $200.0 million to open market repurchases under its existing $1.0 billion authorization. Using a Rule 10b5-1 trading plan automates execution based on preset parameters rather than discretionary timing.
Management highlights a strong balance sheet and cash generation, with cash and cash equivalents of $1,059.8 million as of March 31, 2026. The company plans to complete these repurchases by October 2026, using domestic cash of $206.6 million designated to support the plan.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Planned repurchase size: $200.0 million
Total repurchase program: $1.0 billion
Cash and cash equivalents: $1,059.8 million
+5 more
8 metrics
Planned repurchase size
$200.0 million
Open market common stock repurchases under program
Total repurchase program
$1.0 billion
Board-approved stock repurchase program from April 2025
Cash and cash equivalents
$1,059.8 million
Balance as of March 31, 2026
Domestic cash for plan
$206.6 million
U.S. cash used to support latest trading plan
Foreign cash balance
$853.2 million
Cash and cash equivalents held outside the U.S.
Shares outstanding
71.6 million shares
Common shares outstanding as of March 31, 2026
Doctor customers
299.5 thousand
Approximate number of doctor customers served
Patients treated with Invisalign
22.8 million patients
Cumulative Invisalign patients over 29 years
Key Terms
stock repurchase program, Rule 10b5-1 trading plan, cash and cash equivalents, forward-looking statements, +2 more
6 terms
stock repurchase program financial
"the Company’s $1.0 billion stock repurchase program that was approved"
A stock repurchase program is when a company buys back its own shares from the market. This can make each remaining share more valuable and shows that the company believes its stock is a good investment. It’s like a business treating its shares like a limited resource, hoping to boost confidence and share prices.
Rule 10b5-1 trading plan regulatory
"will be executed pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
cash and cash equivalents financial
"had approximately 71.6 million shares outstanding and $1,059.8 million in cash and cash equivalents"
Cash and cash equivalents are the money a company has on hand plus very short-term, low-risk investments that can be quickly turned into cash, like bank deposits or government bills. Investors watch this figure because it shows a company’s immediate ability to pay bills, cover unexpected costs, and fund operations or growth — like a household’s checking account and emergency fund that keeps daily life running smoothly.
forward-looking statements regulatory
"This news release contains forward-looking statements, including statements regarding"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Nasdaq Global Select Market market
"ALGN | The NASDAQ Stock Market LLC (NASDAQ Global Select Market)"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
emerging growth company regulatory
"405) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
(602 ) 742-2000
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| (NASDAQ Global Select Market) | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
Align Technology, Inc. (the “Company”) announced that it is planning to repurchase $200.0 million of the Company’s common stock through open market repurchases under the Company’s $1.0 billion stock repurchase program that was approved by the Company’s Board of Directors in April 2025. The full text of the press release announcing the foregoing information is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | ||||
99.1 | Press Release of Align Technology, Inc. Announcing $200 Million Open Market Repurchase | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALIGN TECHNOLOGY, INC. | ||||||||
| By: | /s/ John Morici | |||||||
| John Morici Chief Financial Officer and Executive Vice President, Global Finance | ||||||||
Date: April 30, 2026
Exhibit 99.1
Align Technology | Zeno Group | ||||
Madelyn Valente | Sarah Karlson | ||||
(909) 833-5839 | (828) 551-4201 | ||||
mvalente@aligntech.com | sarah.karlson@zenogroup.com | ||||
ALIGN TECHNOLOGY ANNOUNCES $200 MILLION OPEN MARKET REPURCHASE
TEMPE, Ariz., May 1, 2026 -- Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $200.0 million of Align’s common stock through open market repurchases under Align’s $1.0 billion stock repurchase program that was approved by Align’s Board of Directors in April 2025.
“We intend to repurchase $200.0 million of our common stock through open market transactions, reflecting the confidence management and the Board have in our long‑term strategy and growth opportunity,” said John Morici, Align CFO and executive vice president, global finance. “This action underscores the strength of our balance sheet and our ability to generate strong cash flow. We remain focused on executing our strategic priorities, delivering meaningful outcomes for doctors and patients, and creating long‑term stockholder value through sustainable growth and performance. We are operating with a clear focus on disciplined execution—prioritizing the areas we control and continuing to invest thoughtfully in the capabilities and initiatives that will define Align’s future.”
The open market repurchases of Align’s common stock will be executed pursuant to a Rule 10b5-1 trading plan. The timing and number of shares repurchased will be based on an evaluation of market conditions and other factors, including stock price, trading volume, general business and market conditions, and capital availability. The repurchases are expected to be completed by October 2026 and will be funded with Align’s cash on hand. As of March 31, 2026, Align had approximately 71.6 million shares outstanding and $1,059.8 million in cash and cash equivalents, of which $206.6 million is held domestically and is being used to support the open market repurchases under the latest trading plan and $853.2 million is held outside the United States.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Forward-Looking Statements
This news release contains forward-looking statements, including statements regarding: the aggregate value of common stock to be repurchased under the repurchase program; the expected completion date and form of the repurchases; our confidence in our long-term strategy and growth opportunity, and our ability to generate strong cash flow; our ability to focus on executing our strategic priorities, deliver meaningful outcomes for doctors and patients, and create long‑term stockholder value through sustainable growth and performance; our belief that we will continue to invest thoughtfully in capabilities and initiatives that will define Align’s future; our expectation that we will finance the repurchases with cash on hand; as well as other statements regarding the planned open market repurchases under the
- 2 -
repurchase program. Forward-looking statements contained in this press release are based upon information available to Align as of the date hereof. These forward-looking statements reflect our best judgments based on currently known facts and circumstances and are subject to risks and uncertainties, and assumptions that may be inaccurate. As a result, actual results may differ materially and adversely from those expressed or implied in any forward-looking statement.
The foregoing and other risks are detailed from time to time in our periodic reports filed with the Securities and Exchange Commission ("SEC"), including, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 27, 2026. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
- 3 -
FAQ
What stock repurchase did Align Technology (ALGN) announce?
Align Technology plans to repurchase $200.0 million of its common stock through open market transactions under its existing $1.0 billion stock repurchase program. The buybacks will follow a Rule 10b5-1 trading plan and reflect management’s long-term strategy focus.
What is the timeline for Align Technology’s latest buyback plan?
Align expects to complete the $200.0 million open market repurchases by October 2026. Transactions will be executed under a Rule 10b5-1 trading plan, with timing and volume influenced by stock price, trading volume, market conditions, and capital availability.
How large is Align Technology’s overall stock repurchase authorization?
The company’s overall stock repurchase authorization totals $1.0 billion, approved by the Board in April 2025. The newly announced $200.0 million tranche represents a portion of this capacity and will be executed via open market transactions under the program.
Under what trading framework will Align Technology execute the buybacks?
The repurchases will be conducted under a Rule 10b5-1 trading plan, which allows pre-arranged stock transactions based on defined parameters. This structure helps Align systematically repurchase shares while considering market conditions, stock price, trading volume, and other specified factors.